Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if a pair of experimental drugs called botensilimab and balstilimab are safe and effective options for colorectal cancer.
What is the Condition Being Studied?
Colorectal Cancer
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with unresectable or metastatic colorectal cancer
- Do not have metastases to the liver, bone, or brain
- Have not received prior therapy for their current cancer
For more information, contact the study team at justinemae.flores@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Get the study drug balstilimab by IV once every 2 weeks for up to 2 years
- Get the study drug botensilimab by IV on weeks 1, 7, 13, and 19 while you are getting balstilimab
- Receive standard anti-cancer drugs if your cancer does not improve on the study regimen
- Have your tumor biopsied
- Have blood draws
- Have regular CT or MRI scans
Study Details
Full Title
Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00115311
NCT:
NCT06268015
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu